| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2023 | 275 | 4.050 |
Why?
|
| Ovarian Neoplasms | 17 | 2023 | 744 | 3.450 |
Why?
|
| Endometrial Neoplasms | 7 | 2022 | 193 | 2.800 |
Why?
|
| Genital Neoplasms, Female | 4 | 2023 | 107 | 2.390 |
Why?
|
| Carcinoma, Endometrioid | 4 | 2020 | 43 | 2.100 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2023 | 27 | 1.930 |
Why?
|
| Uterine Neoplasms | 5 | 2022 | 227 | 1.450 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 239 | 1.440 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 3 | 2020 | 18 | 1.210 |
Why?
|
| Thyroid Neoplasms | 4 | 2019 | 408 | 1.180 |
Why?
|
| Biomarkers, Tumor | 7 | 2020 | 1464 | 1.150 |
Why?
|
| Ovary | 5 | 2022 | 258 | 1.120 |
Why?
|
| Immunohistochemistry | 13 | 2021 | 1753 | 1.080 |
Why?
|
| Cytodiagnosis | 4 | 2022 | 42 | 1.070 |
Why?
|
| Female | 53 | 2024 | 44533 | 1.030 |
Why?
|
| Placenta Diseases | 1 | 2024 | 13 | 0.970 |
Why?
|
| Hemangioma | 1 | 2024 | 60 | 0.950 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2020 | 33 | 0.910 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2020 | 23 | 0.910 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2017 | 74 | 0.860 |
Why?
|
| Adenocarcinoma | 4 | 2018 | 1169 | 0.850 |
Why?
|
| Teratoma | 2 | 2023 | 50 | 0.840 |
Why?
|
| Carcinoma | 2 | 2016 | 436 | 0.830 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 8 | 0.810 |
Why?
|
| Ascitic Fluid | 2 | 2022 | 37 | 0.800 |
Why?
|
| Humans | 63 | 2024 | 86644 | 0.780 |
Why?
|
| Gynecology | 1 | 2023 | 124 | 0.780 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 47 | 0.770 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2020 | 5 | 0.740 |
Why?
|
| Epithelioid Cells | 1 | 2020 | 13 | 0.730 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2021 | 426 | 0.720 |
Why?
|
| Cervix Uteri | 4 | 2023 | 65 | 0.720 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2021 | 93 | 0.720 |
Why?
|
| Mucolipidoses | 1 | 2019 | 3 | 0.710 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2019 | 11 | 0.710 |
Why?
|
| Papillomaviridae | 2 | 2023 | 153 | 0.690 |
Why?
|
| Middle Aged | 24 | 2023 | 25028 | 0.680 |
Why?
|
| Lymph Nodes | 1 | 2022 | 533 | 0.660 |
Why?
|
| Receptors, Glucocorticoid | 5 | 2024 | 120 | 0.640 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 8 | 0.640 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 52 | 0.630 |
Why?
|
| Urologic Neoplasms | 1 | 2019 | 77 | 0.630 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2017 | 8 | 0.610 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2019 | 164 | 0.600 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1384 | 0.590 |
Why?
|
| Placenta | 3 | 2024 | 175 | 0.560 |
Why?
|
| Adult | 21 | 2023 | 25648 | 0.560 |
Why?
|
| Mucins | 1 | 2016 | 39 | 0.550 |
Why?
|
| Papanicolaou Test | 2 | 2021 | 38 | 0.550 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 3 | 0.530 |
Why?
|
| SOXE Transcription Factors | 1 | 2015 | 5 | 0.530 |
Why?
|
| Nestin | 1 | 2015 | 18 | 0.530 |
Why?
|
| Specimen Handling | 2 | 2022 | 98 | 0.530 |
Why?
|
| Inhibins | 1 | 2015 | 37 | 0.530 |
Why?
|
| Hypertension | 1 | 2024 | 1141 | 0.520 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1208 | 0.520 |
Why?
|
| S100 Proteins | 1 | 2015 | 50 | 0.520 |
Why?
|
| Fibroma, Ossifying | 1 | 2014 | 5 | 0.500 |
Why?
|
| Atypical Squamous Cells of the Cervix | 1 | 2013 | 1 | 0.470 |
Why?
|
| Aged | 18 | 2023 | 18415 | 0.470 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2014 | 51 | 0.470 |
Why?
|
| Pregnancy | 5 | 2024 | 2894 | 0.460 |
Why?
|
| Osteosarcoma | 1 | 2014 | 158 | 0.450 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6509 | 0.440 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 36 | 0.420 |
Why?
|
| Leiomyosarcoma | 2 | 2022 | 40 | 0.410 |
Why?
|
| Retrospective Studies | 9 | 2024 | 8489 | 0.410 |
Why?
|
| Prognosis | 10 | 2023 | 3679 | 0.410 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 322 | 0.400 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 246 | 0.400 |
Why?
|
| Pathologists | 2 | 2024 | 24 | 0.380 |
Why?
|
| Embolism, Fat | 1 | 2010 | 2 | 0.370 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 1056 | 0.370 |
Why?
|
| Peritoneal Lavage | 2 | 2022 | 10 | 0.370 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1565 | 0.370 |
Why?
|
| Fractures, Compression | 1 | 2010 | 17 | 0.370 |
Why?
|
| Thoracic Vertebrae | 1 | 2010 | 49 | 0.360 |
Why?
|
| Neoplasm Staging | 6 | 2023 | 1939 | 0.360 |
Why?
|
| Young Adult | 7 | 2020 | 5976 | 0.350 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 111 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 318 | 0.340 |
Why?
|
| Peritoneal Neoplasms | 2 | 2023 | 177 | 0.330 |
Why?
|
| Cancer-Associated Fibroblasts | 2 | 2019 | 36 | 0.330 |
Why?
|
| Hysterectomy | 3 | 2019 | 146 | 0.330 |
Why?
|
| Proteomics | 3 | 2020 | 212 | 0.320 |
Why?
|
| Neoplasm Invasiveness | 4 | 2023 | 552 | 0.310 |
Why?
|
| Brain | 1 | 2018 | 2216 | 0.310 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2018 | 45 | 0.310 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 394 | 0.300 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 1376 | 0.300 |
Why?
|
| Fallopian Tubes | 3 | 2022 | 41 | 0.290 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2426 | 0.290 |
Why?
|
| Curettage | 2 | 2018 | 12 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 456 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2022 | 1197 | 0.290 |
Why?
|
| Biopsy | 4 | 2019 | 1163 | 0.290 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2023 | 1076 | 0.280 |
Why?
|
| Phenylthiohydantoin | 2 | 2024 | 41 | 0.280 |
Why?
|
| Infant, Newborn | 2 | 2024 | 2380 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2023 | 104 | 0.270 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 486 | 0.270 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 853 | 0.270 |
Why?
|
| Benzamides | 2 | 2024 | 229 | 0.260 |
Why?
|
| Epithelial Cells | 3 | 2018 | 669 | 0.250 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 2262 | 0.240 |
Why?
|
| Papilloma | 1 | 2023 | 22 | 0.230 |
Why?
|
| Lung | 1 | 2010 | 1170 | 0.230 |
Why?
|
| Lymph Node Excision | 2 | 2022 | 217 | 0.230 |
Why?
|
| Postmenopause | 2 | 2022 | 98 | 0.230 |
Why?
|
| Rare Diseases | 2 | 2020 | 59 | 0.220 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 64 | 0.220 |
Why?
|
| Vaginal Smears | 1 | 2023 | 68 | 0.220 |
Why?
|
| DNA Mismatch Repair | 2 | 2019 | 52 | 0.200 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 15 | 0.200 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2021 | 7 | 0.200 |
Why?
|
| Submandibular Gland | 1 | 2021 | 16 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 1 | 2023 | 220 | 0.200 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 25 | 0.200 |
Why?
|
| Parotid Neoplasms | 1 | 2021 | 17 | 0.200 |
Why?
|
| Parotid Gland | 1 | 2021 | 31 | 0.190 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2020 | 4 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 298 | 0.190 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2020 | 15 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1673 | 0.190 |
Why?
|
| Glioma | 1 | 2023 | 285 | 0.190 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 503 | 0.190 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2021 | 62 | 0.190 |
Why?
|
| Chromatin | 2 | 2022 | 380 | 0.190 |
Why?
|
| Receptors, Estrogen | 2 | 2019 | 384 | 0.190 |
Why?
|
| Phenotype | 4 | 2019 | 2378 | 0.190 |
Why?
|
| Point Mutation | 1 | 2021 | 246 | 0.190 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 26 | 0.180 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2019 | 4 | 0.180 |
Why?
|
| Puberty, Delayed | 1 | 2019 | 19 | 0.180 |
Why?
|
| Amenorrhea | 1 | 2019 | 27 | 0.180 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 17 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2021 | 2767 | 0.180 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 12 | 0.180 |
Why?
|
| Glycolysis | 2 | 2018 | 129 | 0.180 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 42 | 0.180 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1991 | 0.180 |
Why?
|
| Pregnancy, Twin | 1 | 2019 | 7 | 0.180 |
Why?
|
| Endometrial Hyperplasia | 1 | 2019 | 8 | 0.180 |
Why?
|
| Adnexal Diseases | 1 | 2019 | 17 | 0.180 |
Why?
|
| Nicotinamide N-Methyltransferase | 1 | 2019 | 6 | 0.180 |
Why?
|
| Genotyping Techniques | 1 | 2020 | 68 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 2019 | 679 | 0.170 |
Why?
|
| Twins | 1 | 2019 | 65 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 69 | 0.170 |
Why?
|
| Pelvic Exenteration | 1 | 2019 | 5 | 0.170 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 43 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 592 | 0.170 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Mesonephroma | 1 | 2018 | 5 | 0.170 |
Why?
|
| Adipocytes | 1 | 2020 | 155 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 80 | 0.160 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 79 | 0.160 |
Why?
|
| Leiomyoma | 1 | 2022 | 191 | 0.160 |
Why?
|
| Genomics | 2 | 2021 | 720 | 0.160 |
Why?
|
| Glycogen | 1 | 2018 | 59 | 0.160 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 30 | 0.160 |
Why?
|
| Triage | 1 | 2019 | 108 | 0.160 |
Why?
|
| Fetus | 1 | 2019 | 226 | 0.160 |
Why?
|
| Thyroid Nodule | 2 | 2019 | 51 | 0.160 |
Why?
|
| DNA | 1 | 2024 | 1294 | 0.160 |
Why?
|
| Cystectomy | 1 | 2019 | 102 | 0.160 |
Why?
|
| Mammary Glands, Animal | 1 | 2018 | 78 | 0.160 |
Why?
|
| Salpingo-oophorectomy | 1 | 2017 | 3 | 0.150 |
Why?
|
| Adenoma | 1 | 2019 | 235 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2022 | 1565 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 534 | 0.150 |
Why?
|
| Metformin | 1 | 2019 | 128 | 0.150 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 61 | 0.150 |
Why?
|
| Mice, Nude | 4 | 2020 | 790 | 0.140 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2016 | 4 | 0.140 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2016 | 35 | 0.140 |
Why?
|
| Transcriptome | 2 | 2018 | 580 | 0.140 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 184 | 0.140 |
Why?
|
| Mutation | 4 | 2021 | 3968 | 0.140 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1578 | 0.140 |
Why?
|
| Seizures | 1 | 2018 | 297 | 0.130 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 200 | 0.130 |
Why?
|
| Mitosis | 1 | 2016 | 153 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 329 | 0.130 |
Why?
|
| Neoplasms | 3 | 2022 | 2898 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 621 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2022 | 2261 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2018 | 313 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2019 | 2903 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2020 | 629 | 0.130 |
Why?
|
| Male | 8 | 2024 | 40966 | 0.120 |
Why?
|
| Tarsal Bones | 1 | 2014 | 9 | 0.120 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 49 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 80 | 0.120 |
Why?
|
| Genotype | 1 | 2019 | 1851 | 0.120 |
Why?
|
| Mice | 7 | 2024 | 11352 | 0.120 |
Why?
|
| Pathology | 1 | 2014 | 30 | 0.120 |
Why?
|
| Minichromosome Maintenance Proteins | 1 | 2013 | 2 | 0.120 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2013 | 20 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 235 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 458 | 0.110 |
Why?
|
| Animals | 10 | 2024 | 26582 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2013 | 165 | 0.110 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 158 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 2360 | 0.110 |
Why?
|
| Adolescent | 3 | 2020 | 8981 | 0.110 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 357 | 0.110 |
Why?
|
| Time Factors | 2 | 2020 | 5210 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2010 | 293 | 0.110 |
Why?
|
| Apoptosis | 2 | 2016 | 1683 | 0.110 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2011 | 3 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 435 | 0.100 |
Why?
|
| Cell Survival | 3 | 2020 | 969 | 0.100 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2011 | 9 | 0.100 |
Why?
|
| Immune Tolerance | 1 | 2014 | 337 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 295 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 325 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 213 | 0.100 |
Why?
|
| Interferon Regulatory Factors | 1 | 2011 | 67 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7993 | 0.100 |
Why?
|
| Nitriles | 2 | 2024 | 149 | 0.090 |
Why?
|
| Receptors, Androgen | 2 | 2024 | 113 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 1531 | 0.090 |
Why?
|
| Coculture Techniques | 2 | 2020 | 164 | 0.080 |
Why?
|
| Gene Expression | 1 | 2013 | 1284 | 0.080 |
Why?
|
| Jejunal Neoplasms | 1 | 2008 | 9 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 813 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 188 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 418 | 0.080 |
Why?
|
| Intestinal Obstruction | 1 | 2008 | 88 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 459 | 0.070 |
Why?
|
| Observer Variation | 2 | 2021 | 602 | 0.070 |
Why?
|
| United States | 2 | 2016 | 6672 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 468 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2024 | 3241 | 0.070 |
Why?
|
| Cell Movement | 2 | 2019 | 758 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2020 | 628 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 1135 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3640 | 0.060 |
Why?
|
| Ascites | 1 | 2023 | 55 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2022 | 40 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2022 | 78 | 0.050 |
Why?
|
| Formaldehyde | 1 | 2022 | 52 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2705 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2232 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2024 | 352 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 204 | 0.050 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 13 | 0.050 |
Why?
|
| Azure Stains | 1 | 2021 | 6 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 134 | 0.050 |
Why?
|
| Methylene Blue | 1 | 2021 | 18 | 0.050 |
Why?
|
| Xanthenes | 1 | 2021 | 23 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 381 | 0.050 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 8 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 124 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2021 | 79 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2271 | 0.050 |
Why?
|
| Carcinogenesis | 1 | 2022 | 195 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 50 | 0.050 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 22 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 68 | 0.050 |
Why?
|
| Heterografts | 1 | 2020 | 98 | 0.040 |
Why?
|
| Omentum | 1 | 2020 | 71 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 68 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2019 | 37 | 0.040 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2019 | 9 | 0.040 |
Why?
|
| S-Adenosylmethionine | 1 | 2019 | 15 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 15 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 236 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 148 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 286 | 0.040 |
Why?
|
| Incidence | 1 | 2023 | 1577 | 0.040 |
Why?
|
| Niacinamide | 1 | 2019 | 116 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 73 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 112 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 207 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 153 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 289 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 196 | 0.040 |
Why?
|
| RNA | 1 | 2022 | 560 | 0.040 |
Why?
|
| Sphingosine | 1 | 2019 | 71 | 0.040 |
Why?
|
| Lysophospholipids | 1 | 2019 | 63 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 504 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2024 | 1981 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 292 | 0.040 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2018 | 54 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 192 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 151 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 165 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2019 | 502 | 0.040 |
Why?
|
| Thyroid Gland | 1 | 2019 | 270 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 266 | 0.040 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 33 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 712 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 311 | 0.040 |
Why?
|
| Chemoprevention | 1 | 2017 | 91 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 266 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 72 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2016 | 71 | 0.040 |
Why?
|
| Ontario | 1 | 2016 | 52 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 696 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2016 | 79 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 547 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 378 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 156 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1830 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 535 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1456 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1219 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1041 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 937 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2016 | 217 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1019 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2014 | 77 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1538 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1204 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 96 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2818 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 168 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 930 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 166 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1863 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 1313 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 782 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 407 | 0.030 |
Why?
|
| Antibodies | 1 | 2014 | 350 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1047 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1458 | 0.030 |
Why?
|
| Child | 1 | 2023 | 6927 | 0.030 |
Why?
|
| Rats | 1 | 2018 | 3990 | 0.030 |
Why?
|
| Phylogeny | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5417 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3092 | 0.020 |
Why?
|